VolitionRX Third Quarter Results

Good Call Media’s Nik Wood hosted a video interview with Volition’s CEO, Cameron Reynolds to introduce the company’s third quarter results.

Click here to see the video

Video has become part of the central communication strategy adopted by Volition. Cameron Reynolds commented:

“I could not be more proud of our dedicated team at Volition, and the ground-breaking work we are doing. I’m happy to say that we have made excellent progress this quarter on our platform development, Nu.Q^TMCapture, Nu.Q^TMVet and our colorectal cancer and lung cancer trials, particularly in Asia, and we reported our first revenues from sales of Research Use Only kits and the provision of contract research services.”

He added that Volition are an epigenetics company focused on advancing the science of epigenetics and exploiting these advances in human and animal health. This has been our mission since our founding, and it is coming to fruition with our Nu.Q^TMplatform at the very heart of epigenetics. We believe the last decade of work and our extensive intellectual property portfolio puts Volition in a strong position to be a significant player in this field by launching multiple products.”

Watch out for further video updates from VolitionRX coming soon.